An injectable HIV-prevention drug is highly effective - NBC News
Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...
This HIV drug is hailed as 2024's Discovery of the Year - MSN
Gilead, the manufacturer of Lenacapavir, announced a voluntary licensing agreement with several generic drug manufacturers to produce and supply generic versions of Lenacapavir in 120 developing ...
Twice-yearly shot proves successful at preventing HIV infection …
Jul 24, 2024 · Phase 3 trial data shows that a twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections. Two shots a year of a drug currently used to treat HIV...
Anti-HIV drug lenacapavir called 'breakthrough of the year ... - NPR
Dec 12, 2024 · But 2024 has fueled increasing optimism among leading infectious disease experts after the results of two groundbreaking clinical trial results for a drug called lenacapavir showed it to be...
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
Sep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
Lenacapavir injection lowers HIV risk by 96% - Medical News Today
Dec 3, 2024 · One study revealed that injection of the medication lenacapavir every six months could greatly reduce the risk for HIV infection among at-risk individuals.
Long-acting injectable lenacapavir continues to show promising …
Sep 26, 2024 · WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
Gileads Twice Yearly Lenacapavir Demonstrated 100 Efficacy and ...
Jun 20, 2024 · PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada ® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and background HIV incidence (bHIV).
Gilead Presents Full PURPOSE 2 Data Results for Twice Yearly ...
Nov 13, 2024 · Those previously reported data showed that lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV), with two incident cases among 2,179 participants, corresponding to 99.9% of participants not …
New HIV drug can only offer hope of ending AIDS if all have …
GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.